BiotechTube

Golimumab

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Spondylitis, Ankylosing

Conditions

Spondylitis, Ankylosing, Arthritis, Psoriatic

Trial Timeline

Jan 7, 2019 → Nov 15, 2021

NCT ID
NCT03733925

About Golimumab

Golimumab is a approved stage product being developed by Johnson & Johnson for Spondylitis, Ankylosing. The current trial status is completed. This product is registered under clinical trial identifier NCT03733925. Target conditions include Spondylitis, Ankylosing, Arthritis, Psoriatic.

What happened to similar drugs?

20 of 20 similar drugs in Spondylitis, Ankylosing were approved

Approved (20) Terminated (4) Active (0)
✅Tramadol /acetaminophen + DiclofenacJohnson & JohnsonApproved
✅InfliximabMerckApproved
✅GolimumabMerckApproved
✅RemicadeMerckApproved
✅RemicadeMerckApproved
✅InfliximabMerckApproved
✅InfliximabMerckApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03733925ApprovedCompleted

Competing Products

20 competing products in Spondylitis, Ankylosing

See all competitors
ProductCompanyStageHype Score
InfliximabCelltrionPhase 1
29
InfliximabCelltrionPhase 1
29
SUNPG1622 I dose + Placebo doseSun PharmaceuticalPhase 2
27
adalimumabEisaiPhase 3
40
Ixekizumab + Placebo + AdalimumabEli LillyPhase 3
32
Tramadol /acetaminophen + DiclofenacJohnson & JohnsonApproved
35
Golimumab + PlaceboJohnson & JohnsonPhase 3
40
SHR0302 + SHR0302 placeboJiangsu Hengrui MedicinePhase 2/3
38
placebo for risankizumab + risankizumabAbbViePhase 2
35
Upadacitinib + PlaceboAbbViePhase 2
35
AdalimumabAbbViePre-clinical
26
infliximab + PlaceboMerckPhase 3
40
InfliximabMerckApproved
35
Infliximab + Placebo + NaproxenMerckPhase 3
40
InfliximabMerckPre-clinical
26
GolimumabMerckApproved
43
RemicadeMerckApproved
43
RemicadeMerckApproved
43
InfliximabMerckApproved
43
InfliximabMerckApproved
35